Skip to content
Radio Logo
PodcastsLife SciencesBiotechTV - News

BiotechTV - News

BiotechTV
Latest episode

514 episodes

  • BiotechTV - News

    Jefferies London 2026: Intellia is currently in front of FDA for the potential approval of the first in vivo (in the body) CRISPR gene editing therapy - it is for hereditary angioedema

    11/16/2026 | 9 mins.
    President & CEO John Leonard discusses the program and compares and contrasts it to more traditional medicines. He also provides an update on the company's transthyretin (ATTR) amyloidosis with cardiomyopathy (ATTR-CM) program.
  • BiotechTV - News

    Jefferies 2026: Nektar Therapeutics has Rezpeg moving full speed ahead in atopic dermatitis and alopecia (and beyond) - the Head of R&D shares learnings about its mechanism

    11/16/2026 | 11 mins.
    Jonathan Zalevsky describes how learnings from the phase 2 AD trial have helped with the study design of three phase 3 studies - and the latest on alopecia. He emphasizes how the company seems to be seeing a deepening of responses from this Treg targeting mechanism over time.
  • BiotechTV - News

    Jefferies 2026: Sofinnova Partners announced today a new $815M fund today that will invest in mostly later stage European companies

    11/16/2026 | 10 mins.
    Managing Partner Graziano Seghezzi tells us about the new fund and what it will invest in, and comments on the environment for European biotech today.
  • BiotechTV - News

    Jefferies London: While its in the middle of the closely watched Attruby launch, BridgeBio has two other medicines in front of FDA and another big phase 3 readout scheduled for later next year

    11/16/2026 | 9 mins.
    Founder & CEO Neil Kumar shares his take on how the Attruby launch is going, and also talks Limb-girdle muscular dystrophy type 2I/R9, achondroplasia, and hypoparathyroidism.
  • BiotechTV - News

    STIFEL 2026: Trace Neuroscience believes that a breakthrough in ALS will be due to restoring expression of a protein called UNC13A, which most ALS patients don't have sufficient due to genetic factors

    11/12/2026 | 8 mins.
    Co-Founder and CEO Eric Green explains the role of UNC13A, and how UNC13A mRNA is improperly spliced for most ALS patients. Trace is currently running a UK/EU phase 1 study of its antisense oligonucleotide that aims to restore expression, and also concurrently an investigator led study in China.
More Life Sciences podcasts
About BiotechTV - News
This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.
Podcast website

Listen to BiotechTV - News, The Quanta Podcast and many other podcasts from around the world with the radio.net app

Get the free radio.net app

  • Stations and podcasts to bookmark
  • Stream via Wi-Fi or Bluetooth
  • Supports Carplay & Android Auto
  • Many other app features
BiotechTV - News: Podcasts in Family